FDA grants rare pediatric disease label to gene therapy for GM1 – Healio
|
FDA grants rare pediatric disease label to gene therapy for GM1
Healio LYS-GM101 (Lysogene) is a gene therapy candidate for the treatment of GM1 that may help replace the defective GLB1 gene in the cells of affected children. This therapy is intended to encourage functional enzyme production and prevent further … |
